Skip to main content

Independent service, not a government website.

Federal grantForecast (not open yet)Grant forecast

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

Department of Health and Human Services, National Institutes of Health

Forecast: expected to post Mar 1, 2027

This is a Grants.gov forecast: the agency plans to post this funding opportunity, but applications are not open yet. Dates and amounts are the agency's estimates and can change. When it is posted on Grants.gov, this page updates to the posted grant.

Forecast details

Status
Forecast: expected to post Mar 1, 2027
Estimated post date
Mar 1, 2027
Estimated application due date
May 25, 2027
Estimated award date
Apr 1, 2028
Estimated project start
Apr 1, 2028
Fiscal year
2028
Forecast posted
Sep 23, 2026
Funding opportunity number
RFA-NS-28-009
Grants.gov ID
363926
Funding instrument
Cooperative Agreement
Category of funding
Health
Opportunity category
Discretionary
Award ceiling
Not stated
Award floor
Not stated
Total program funding
Not stated
Expected awards
Not stated
Cost sharing required
No
Assistance Listing (ALN/CFDA)
  • 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders

Who can apply

Businesses are among the eligible applicants listed on Grants.gov.

  • Public and State controlled institutions of higher education
  • State governments
  • Small businesses
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • County governments
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • Private institutions of higher education
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Special district governments
  • For profit organizations other than small businesses
  • City or township governments
  • Native American tribal governments (Federally recognized)

Additional information on eligibility

Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial (designed to provide pivotal data to establish substantial evidence of effectiveness in support of a marketing application) supported by a U.S. based small business concern that is the FDA-designated sponsor of a drug or biological product which is the subject of an IND under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) to prevent, diagnose, mitigate, treat, or cure ALS. The definition of a small business concern can be found in section 3(a) of the Small Business Act (15 U.S.C. 632(a)).Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services.

Description

Announcement and documents

No attachments listed in the Grants.gov data. Check the official listing for documents.

Grantor contact

The agency contact for this forecast is listed on the official Grants.gov forecast. We don't copy personal contact details from forecasts.

Grants: Grants.gov (federal grant opportunities) · last updated Nov 20, 2026, 4:20 PM ET.

This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services.

Always confirm details, amendments and deadlines on the official listing. Government Bid Finder is an independent service and is not affiliated with or endorsed by the U.S. government.